Top

Published in:

01-09-2007 | Imagers in Neuron-Oncology Clinical-Patient Studies

[11C] Methionine and [18F] Fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme

Authors: Christian Pötzi, Alexander Becherer, Christine Marosi, Georgios Karanikas, Monika Szabo, Robert Dudczak, Kurt Kletter, Susanne Asenbaum

Published in: Journal of Neuro-Oncology | Issue 3/2007

Abstract

Background

The aim of this study was to evaluate the value of [11C] methionine (MET) and [18F] fluorodeoxyglucose (FDG) PET in the follow-up of glioblastoma multiforme (GBM).

Patients and methods

After surgical and/or conservative treatment, 28 patients (pts) with GBM underwent FDG and MET PET on average 12.7 months after the diagnosis had been established. Scans were evaluated visually and by calculating the maximal tumor SUV as well as the ratio of tumor vs. contralateral region (RTu). The degree of tracer uptake was compared with survival time, disease duration and MRI findings.

Results

The mean overall duration of survival was 12.7 months. The patients were divided into two groups: those that survived less than 12 months and those that survived longer than 12 months. Focally increased uptake was revealed by MET PET in 24 patients and by FDG PET in 2 patients. On MRI scans, viable tumor tissue was suspected in 18 patients. No correlations were registered between FDG/MET uptake and survival time or disease duration respectively; Kaplan–Meier calculations were negative in this regard. Similarly, negative results were obtained in subgroups of patients who had undergone microsurgical resection and whose disease was at least of 6 months’ duration, and additionally in a subgroup who had undergone their last treatment longer than 6 months ago. With respect to survival groups, a positive MET PET was associated with a sensitivity of 86% and a specificity of 8%. SUV and RTu values did not differ between patients with positive or negative MRI results.

Conclusions

In this study FDG PET seems to be of limited value in the work-up of recurrent GBM because of its lower sensitivity than MET PET and the fact that it allows no prediction of the outcome. MET PET visualizes viable tumor tissue without adding any prognostic information and appears to be in no way superior to conventional imaging.

Goldman S, Levivier M, Pirotte B et al (1996) Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. Cancer 78:1098–1106PubMedCrossRef

Di Chiro G, DeLaPaz RL, Brooks RA et al (1982) Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology 32:1323–1329PubMed

Langleben DD, Segall GM (2000) PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 41:1861–1867PubMed

Chao ST, Suh JH, Raja S et al (2001) The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 96:191–197PubMedCrossRef

Benard F, Romsa J, Hustinx R (2003) Imaging gliomas with positron emission tomography and single-photon emission computed tomography. Semin Nucl Med 33:148–162PubMedCrossRef

Ogawa T, Shishido F, Kanno I et al (1993) Cerebral glioma: evaluation with methionine PET. Radiology 186:45–53PubMed

Jager PL, Vaalburg W, Pruim J et al (2001) Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 42:432–445PubMed

Kuwert T, Woesler B, Morgenroth C et al (1998) Diagnosis of recurrent glioma with SPECT and iodine-123-alpha-methyl tyrosine. J Nucl Med 39:23–27PubMed

Schmidt D, Gottwald U, Langen KJ et al (2001) 3-[¹²³I]iodo-alpha-methyl-l-tyrosine uptake in cerebral gliomas: relationship to histological grading and prognosis. Eur J Nucl Med 28:855–861PubMedCrossRef

10.

Ribom D, Engler H, Blomquist E et al (2002) Potential significance of¹¹C-methionine PET as a marker for the radiosensitivity of low-grade gliomas. Eur J Nucl Med Mol Imaging 29:632–640PubMedCrossRef

11.

Riemann B, Papke K, Hoess N et al (2002) Noninvasive grading of untreated gliomas: a comparative study of MR imaging and 3-(iodine 123)-l-alpha-methyltyrosine SPECT. Radiology 225:567–574PubMedCrossRef

12.

De Witte O, Goldberg I, Wikler D et al (2001) Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 95:746–750PubMed

13.

Levivier M, Wikler D Jr, Massager N et al (2002) The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review. J Neurosurg 97:542–550PubMed

14.

Pirotte B, Goldman S, Salzberg S et al (2003) Combined positron emission tomography and magnetic resonance imaging for the planning of stereotactic brain biopsies in children: experience in 9 cases. Pediatr Neurosurg 38:146–155PubMedCrossRef

15.

Young R (1998) The role of the gamma knife in the treatment of malignant primary and metastatic brain tumors. CA Cancer J Clin 48:177–188PubMed

16.

Nishimura R, Takahashi M, Morishita S et al (1992) MR Gd-DTPA enhancement of radiation brain injury. Radiat Med 10:109–116PubMed

17.

Ishiwata K, Ido T, Vaalburg W (1988) Increased amounts of D-enantiomer dependent on alkaline concentration in the synthesis of l-[methyl-11C]methionine. Int J Rad Appl Instrum [A] 39:311–314CrossRef

18.

Chung JK, Kim YK, Kim SK et al (2002) Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging 29:176–182PubMedCrossRef

19.

Herholz K, Holzer T, Bauer B et al (1998) 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology 50:1316–1322PubMed

20.

Kracht LW, Miletic H, Busch S et al (2004) Delineation of brain tumor extent with [11C]l-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 10:7163–7170PubMedCrossRef

21.

Ogawa T, Kanno I, Shishido F et al (1991) Clinical value of PET with¹⁸F-fluorodeoxyglucose and l-methyl-¹¹C-methionine for diagnosis of recurrent brain tumor and radiation injury. Acta Radiol 32:197–202PubMedCrossRef

22.

Van Laere K, Ceyssens S, Van Calenbergh F et al (2005) Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 32:39–51PubMedCrossRef

23.

Kim S, Chung JK, Im SH et al (2005) 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 32:52–59PubMedCrossRef

24.

Nariai T, Tanaka Y, Wakimoto H et al (2005) Usefulness of l-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 103:498–507PubMed

25.

Spence AM, Mankoff DA, Muzi M (2003) Positron emission tomography imaging of brain tumors. Neuroimag Clin N AM 13:717–739CrossRef

26.

Ogawa T, Inugami A, Hatazawa J et al (1996) Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and l-methyl-11C-methionine. AJNR Am J Neuroradiol 17:345–353PubMed

27.

Lichy MP, Henze M, Plathow C et al (2004) Metabolic imaging to follow stereotactic radiation of gliomas – the role of 1H MR spectroscopy in comparison to FDG-PET and IMT-SPECT. Rofo 176:1114–1121PubMed

28.

Woesler B, Kuwert T, Morgenroth C et al (1997) Non-invasive grading of primary brain tumours: results of a comparative study between SPET with 123I-alpha-methyl tyrosine and PET with 18F-deoxyglucose. Eur J Nucl Med 24:428–434PubMed

29.

Rozental JM, Cohen JD, Mehta MP et al (1993) Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. J Neurooncol 15:57–66PubMedCrossRef

30.

Herholz K, Kracht LW, Heiss WD (2003) Monitoring the effect of chemotherapy in a mixed glioma by C-11-methionine PET. J Neuroimaging 13:269–271PubMedCrossRef

31.

Padma MV, Said S, Jacobs M et al (2003) Prediction of pathology and survival by FDG PET in gliomas. J Neurooncol 64:227–237PubMedCrossRef

32.

Roelcke U, Blasberg RG, von Ammon K et al (1998) Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas. J Nucl Med 39:879–884PubMed

33.

De Witte O, Lefranc F, Levivier M et al (2000) FDG-PET as a prognostic factor in high-grade astrocytoma. J Neurooncol 49:157–163PubMedCrossRef

34.

Barker FG 2nd, Chang SM, Valk PE et al (1997) 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 79:115–126PubMedCrossRef

35.

Hammoud MA, Sawaya R, Shi W et al (1996) Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 27:65–73PubMedCrossRef

36.

Tsuyuguchi N, Takami T, Sunada I et al (2004) Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery—in malignant glioma. Ann Nucl Med 18:291–296PubMedCrossRef

37.

Lacroix M, Abi-Said D, Fourney DR F et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198PubMed

38.

Chow KL, Gobin YP, Cloughesy T et al (2000) Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy. AJNR 21:471–478PubMed

39.

Keles GE, Anderson B, Berger MS (1999) The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 52:371–379PubMedCrossRef

Title: [11C] Methionine and [18F] Fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme
Authors: Christian Pötzi
Alexander Becherer
Christine Marosi
Georgios Karanikas
Monika Szabo
Robert Dudczak
Kurt Kletter
Susanne Asenbaum
Publication date: 01-09-2007
Publisher: Kluwer Academic Publishers-Plenum Publishers
Published in: Journal of Neuro-Oncology / Issue 3/2007
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-007-9375-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

[11C] Methionine and [18F] Fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme

Abstract

Background

Patients and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2007

Increasing of HER2 membranar density in human glioblastoma U251MG cell line established in a new nude mice model

Differential effect of surgery and radiotherapy on neurocognitive functioning and health-related quality of life in WHO grade I meningioma patients

Congenital diffuse anaplastic astrocytoma with ependymal and leptomeningeal spread: case report

The frequency and cause of anxiety and depression amongst patients with malignant brain tumours between surgery and radiotherapy

Discovery of serum biomarkers in astrocytoma by SELDI–TOF MS and proteinchip technology

Association of telomerase gene hTERT polymorphism and malignant gliomas